ProfileGDS5678 / 1434660_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 25% 33% 41% 43% 41% 24% 32% 46% 48% 50% 52% 51% 36% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.6062625
GSM967853U87-EV human glioblastoma xenograft - Control 22.7586533
GSM967854U87-EV human glioblastoma xenograft - Control 32.9355741
GSM967855U87-EV human glioblastoma xenograft - Control 42.9432143
GSM967856U87-EV human glioblastoma xenograft - Control 52.8999841
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.6140224
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.786832
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.0591646
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.1092148
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.18750
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.2721652
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.1907251
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.8172536
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9837743